Merrimack Pharmaceuticals (MACK) Financials

$15.13

$0.00 (0.00%)

As on 28-May-2024 09:30EDT

Market cap

$224 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

11.4

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Operating Revenue	--	--	-0.45	--	--	--
Cost of Revenue	--	--	0.45	--	--	2.23
Gross Profit	--	--	-0.45	--	--	-2.23
Operating Expenses	2.26	2.18	2.17	2.62	5.01	27.27
Operating Profit (EBIT)	-2.26	-2.18	-1.73	-2.47	-2.87	-22.36
Other Income	0.18	--	0.19	--	-0.14	1.15
Profit before Tax	-1.33	-1.17	-1.54	-2.45	-3.01	-22.74
Provision for Tax	23.20	0.01	0.00	0.00	0.01	-1.47
Profit after Tax (Net Income)	-24.54	-1.18	-1.54	-2.46	-3.03	-21.27
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-0.39	--	-1.54	-2.46	-3.03	-17.33

Liabilities ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Shareholder's Funds	221.65	18.75	19.25	14.19	16.01	17.31
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	--	--	0.59	0.12	0.12	0.27
Current Liabilities	22.67	0.44	0.59	0.56	0.77	2.77
Total Liabilities	266.99	19.19	19.84	14.75	16.78	20.08

Assets ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Non-Current Assets	0.00	0.00	0.01	0.07	0.23	1.39
Current Assets	244.32	19.18	19.83	14.68	16.54	18.69
Total Assets	266.99	19.19	19.84	14.75	16.78	20.08
Total Debt*	--	--	--	--	--	--
Net Current Assets	221.65	18.74	19.24	14.12	15.77	15.92

Cashflow ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Cash From Operating Activities	--	-1.52	-1.74	-0.22	-4.63	-31.37
Cash Flow from Investing Activities	--	--	0.45	0.14	2.14	69.83
Cash from Financing Activities	--	0.52	6.53	0.24	-0.06	-42.54
Net Cash Inflow / Outflow	--	--	5.24	--	-2.54	-4.08

Financials Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Adjusted EPS ($)	-1.75	-0.08	-0.11	-0.19	-0.23	-1.64
Cash EPS ($)	--	-0.08	-0.11	-0.19	-0.23	-1.46
Adjusted Book Value ($)	--	1.34	1.37	1.09	1.23	1.33
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.11	-0.12	-0.02	-0.36	-2.41
Free Cash Flow per Share ($)	--	-0.11	-0.12	-0.02	-0.36	-2.41

Profitability Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
ROCE (%)	--	-6.22	-9.24	-16.26	-18.18	-46.74
ROE (%)	-20.41	-6.22	-9.24	-16.26	-18.18	-55.87
ROA (%)	-17.10	-6.05	-8.93	-15.57	-16.43	-39.16
EBIT Margin (%)	--	--	388.54	--	--	--
Net Margin (%)	-13,786.52	--	600.78	--	2,147.52	-1,854.14
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Revenue Growth (%)	--	1.00	--	--	--	--
EBIT Growth (%)	1.94	-151.71	30.06	13.96	87.15	66.88
Net Profit Growth (%)	-1,695.17	23.51	37.11	18.92	85.76	47.50
EPS Growth (%)	-1,619.69	0.24	0.42	0.19	0.86	0.47
Book Value Growth (%)	1,056.11	--	--	--	--	--

Valuation Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Price / Earnings	--	-158.97	-103.91	-20.70	-29.58	-1.93
Price / Book Value	11.38	10.01	8.34	3.58	5.60	2.37
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-89.40	-77.60	-53.84	-13.27	-14.66	-1.02
Close Price ($)	14.77	13.41	11.46	3.91	6.89	3.15
High Price ($)	15.89	13.52	13.66	9.45	8.86	6.19
Low Price ($)	11.53	11.01	3.00	3.68	1.49	2.99
Market Cap ($ Cr)	223.75	--	--	--	--	--

Solvency Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Debt to Equity	--	--	--	--	--	--
Short term debt to equity ratio	--	--	--	--	0.83	--
Current Ratio	10.78	43.50	33.66	26.13	21.49	6.75
Quick Ratio	10.78	--	--	--	--	--
Interest Coverage	-6.58	--	-9.20	-123.60	-20.38	-14.63

Operating Efficiency Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	-0.03	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	--	126.40	--	--	106.97
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.